P2RY1: A G-Protein-Coupled Receptor for Pain and Inflammation

Target Name: P2RY1

NCBI ID: G5028

P2RY1

P2RY1: A G-Protein-Coupled Receptor for Pain and Inflammation

Introduction

Purinergic receptors, a subfamily of G-protein-coupled receptors (GPCRs), play a crucial role in pain modulation, inflammation, and neurodegenerative diseases. The P2Y family of purinergic receptors is one of the most well-studied GPCR families, with four structurally similar subfamilies: P2Y1, P2Y2, P2Y3, and P2Y4. P2Y1R, also known as P2RY1, is the first member of the P2Y1 family and is expressed in various tissues, including brain, heart, skeletal muscles, and peripheral nerves. P2Y1R is a GPCR that functions as a receptor for small molecules such as agonists and antagonists, leading to modulation of various physiological processes, including pain perception, inflammation, and neurotransmission.

Purinergic receptors are a diverse family of GPCRs that play a crucial role in cellular signaling. They are characterized by the presence of a catalytic 伪-helices, a transmembrane region, and an extracellular portion that is involved in ligand binding. P2Y1R is a small GPCR that is expressed in various tissues and is involved in pain modulation, inflammation, and neurotransmission.

Pain perception is a complex process that involves the activation of multiple neural populations, including nociceptors, pain modulators, and the central nervous system. P2Y1R is involved in the modulation of pain perception by agonists, which activate the nociceptors and activate the P2Y1R to transmit pain signals to the central nervous system.

In addition to its role in pain perception, P2Y1R is also involved in the modulation of inflammation. Chronic pain is associated with an increased risk of inflammation and the development of inflammatory diseases, including rheumatoid arthritis, osteoarthritis, and cancer. P2Y1R is involved in the modulation of inflammation by antagonists, which reduce the production of pro-inflammatory cytokines and chemokines.

P2Y1R is also involved in neurotransmission, specifically in the modulation of neurotransmitter release and neurotransmission. The neurotransmitter acetylcholine is a well-known neurotransmitter that is involved in memory, attention, and motor function. of neurotransmission by agonists, which increase the release of acetylcholine and modulate its effects.

Despite its involvement in various physiological processes, P2Y1R is a potent drug target for pain and inflammation. The identification of small molecules that can modulate P2Y1R activity provides a new avenue for the development of therapeutic agents for pain and inflammation.

P2RY1 antagonists

P2Y1R antagonists are small molecules that can inhibit the activity of P2Y1R, including agonists and antagonists. P2Y1R antagonists have been shown to be effective in the modulation of pain and inflammation. For example, experiments have shown that P2Y1R antagonists can effectively alleviate pain in experimental models of pain. Additionally, P2Y1R antagonists have been shown to be effective in reducing inflammation in various experimental models of inflammation.

P2Y1R agonists

P2Y1R agonists are small molecules that can activate the activity of P2Y1R, leading to the modulation of pain and inflammation. P2Y1R agonists have been shown to be effective in the modulation of pain and inflammation in experimental models.

P2Y1R antagonists have been shown to interact

Protein Name: Purinergic Receptor P2Y1

Functions: Receptor for extracellular adenine nucleotides such as ADP (PubMed:9442040, PubMed:9038354, PubMed:25822790). In platelets, binding to ADP leads to mobilization of intracellular calcium ions via activation of phospholipase C, a change in platelet shape, and ultimately platelet aggregation (PubMed:9442040)

The "P2RY1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about P2RY1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets